Cargando…

Accelerating Patients’ Access to Advanced Therapies in the EU

Detalles Bibliográficos
Autores principales:	Elsanhoury, Ahmed, Sanzenbacher, Ralf, Reinke, Petra, Abou-El-Enein, Mohamed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609878/ https://www.ncbi.nlm.nih.gov/pubmed/28971109 http://dx.doi.org/10.1016/j.omtm.2017.08.005

Ejemplares similares

Telbivudine in chronic lymphocytic myocarditis and human parvovirus B19 transcriptional activity
por: Van Linthout, Sophie, et al.
Publicado: (2018)

Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals
por: Elsallab, Magdi, et al.
Publicado: (2020)

Cell and Gene Therapy Trials: Are We Facing an ‘Evidence Crisis’?
por: Abou-El-Enein, Mohamed, et al.
Publicado: (2019)

Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell‐Based Interventions
por: Bauer, Gerhard, et al.
Publicado: (2018)

EU R&D for Accelerators
por: Aleksan, Roy
Publicado: (2011)

Targeting CD20+ B-lymphocytes in inflammatory dilated cardiomyopathy with rituximab improves clinical course: a case series
por: Tschöpe, Carsten, et al.
Publicado: (2019)

Bringing base editing to the clinic: The next generation of genome editors
por: Flugel, Christian L., et al.
Publicado: (2023)

A Toolbox of Potential Immune-Related Therapies for Inflammatory Cardiomyopathy
por: Elsanhoury, Ahmed, et al.
Publicado: (2020)

EuCARDWP4 -Accelerator Networks
por: Zimmermann, F, et al.
Publicado: (2010)

Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Choe, Jee H., et al.
Publicado: (2022)

Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration
por: Kabeel, Mamdouh M, et al.
Publicado: (2008)

EuCARD 2010 Accelerator Technology in Europe
por: Romaniuk, R S
Publicado: (2010)

EuCARD WP4 Accelerator Networks
por: Zimmermann, F, et al.
Publicado: (2010)

Unproven stem cell interventions: A global public health problem requiring global deliberation
por: Master, Zubin, et al.
Publicado: (2021)

Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges
por: Tschöpe, Carsten, et al.
Publicado: (2022)

Hourly-block and standard patient scheduling systems at two private hospitals in Alexandria
por: Zaghloul, Ashraf Ahmad Zaher, et al.
Publicado: (2010)

EuCARD and CARE - development of accelerator technology in Poland
por: Romaniuk, Ryszard
Publicado: (2009)

Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma
por: Ning, Yang‐Min, et al.
Publicado: (2017)

CAR NK-92 cell–mediated depletion of residual TCR(+) cells for ultrapure allogeneic TCR-deleted CAR T-cell products
por: Kath, Jonas, et al.
Publicado: (2023)

Migrant’s access to preventive health services in five EU countries
por: Rosano, Aldo, et al.
Publicado: (2017)

Advanced Therapy Medicinal Products' Translation in Europe: A Developers' Perspective
por: Pizevska, Maja, et al.
Publicado: (2022)

Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis
por: Elsallab, Magdi, et al.
Publicado: (2023)

Accelerator physicists take the long view at EuCARD’13
por: O'Luanaigh, C, et al.
Publicado: (2013)

Nurse stress at two different organizational settings in Alexandria
por: Zaghloul, Ashraf AZ, et al.
Publicado: (2009)

Renewable energy policy in the EU member states and the accession states
por: Reiche, D
Publicado: (2003)

AIDA makes EU-funded access to European facilities available
Publicado: (2012)

Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries
por: Canales Albendea, Miguel Á., et al.
Publicado: (2023)

Does Europe Need an EU Product Safety Directive for Access Scaffolding?
por: Rubio-Romero, Juan Carlos, et al.
Publicado: (2019)

The persistence of legal uncertainty on EU citizens’ access to social benefits in Germany
por: Gago, Angie, et al.
Publicado: (2022)

Recent trends and developments in the case law of EU Courts on access to documents
por: Marcoulli, Anna, et al.
Publicado: (2023)

Over-the-counter medication patterns in households in Sharjah, United Arab Emirates
por: Zaghloul, Ashraf Ahmad, et al.
Publicado: (2013)

Access Governance for Biobanks: The Case of the BioSHaRE-EU Cohorts
por: Kaye, Jane, et al.
Publicado: (2016)

Challenges and opportunities for continued access to effective antibiotics - what role for the EU?
por: Anderson, M, et al.
Publicado: (2023)

Design and development of the Transnational Access web portal for RADNEXT EU Project
por: Ciesielski, Tymoteusz Igor
Publicado: (2021)

EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation
por: Detela, Giulia, et al.
Publicado: (2019)

From discovery to approval of an advanced therapy medicinal product-containing stem cells, in the EU
por: Pellegrini, Graziella, et al.
Publicado: (2016)

Do EU Member States Care About their Diasporas’ Access to Social Protection? A Comparison of Consular and Diaspora Policies across EU27
por: Lafleur, Jean-Michel, et al.
Publicado: (2020)

Obligation towards medical errors disclosure at a tertiary care hospital in Dubai, UAE
por: Zaghloul, Ashraf Ahmad, et al.
Publicado: (2016)

Development of accelerator technology in Poland, Impact of European CARE and EuCARD projects
por: Romaniuk, R
Publicado: (2008)

Cross-Border Access to Clinical Trials in the EU: Exploratory Study on Needs and Reality
por: Lalova, Teodora, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_59eggru45h9gcie89mpm77j3cc